← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA3618.1x25.1x36.8x
EV / LTM revenue731.5x2.8x5.3x
Premium to unaffected price8223%33%52%
Premium to 30-day VWAP1129%42%48%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
08162009: 1 deals, 0 clean on every measure200912010: 14 deals, 1 clean on every measure2010142011: 12 deals, 5 clean on every measure2011122012: 5 deals, 4 clean on every measure201252013: 7 deals, 5 clean on every measure201372014: 10 deals, 5 clean on every measure2014102015: 6 deals, 2 clean on every measure201562016: 11 deals, 8 clean on every measure2016112017: 9 deals, 7 clean on every measure201792018: 8 deals, 6 clean on every measure201882019: 3 deals, 3 clean on every measure201932020: 7 deals, 5 clean on every measure202072021: 12 deals, 7 clean on every measure2021122022: 5 deals, 3 clean on every measure202252023: 4 deals, 4 clean on every measure202342024: 10 deals, 7 clean on every measure2024102025: 16 deals, 11 clean on every measure2025162026: 7 deals, 3 clean on every measure20267
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 25.3x median across 21 dealsHealthcare25.3xn=21Industrials: 21.4x median across 14 dealsIndustrials21.4xn=14
Deals by sector
Healthcare: 101 dealsHealthcare101Industrials: 42 dealsIndustrials42Technology: 4 dealsTechnology4
Deals by buyer type
Financial sponsor: 6 dealsFinancial sponsor6Strategic: 97 dealsStrategic97Management / founder: 0 dealsManagement / founder0Controlling holder: 1 dealsControlling holder1Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 43 dealsUnclassified43
Deals by enterprise value
Under $250m: 63 dealsUnder $250m63$250m to $1bn: 35 deals$250m to $1bn35$1bn to $5bn: 31 deals$1bn to $5bn31$5bn to $20bn: 16 deals$5bn to $20bn16Over $20bn: 1 dealsOver $20bn1Not computed: 1 dealsNot computed1
Deals by industry code
Business Services & Software: 471 dealsBusiness Services & Sof…471Chemicals, Pharmaceuticals & Allied Products: 294 dealsChemicals, Pharmaceutic…294Depository Institutions: 289 dealsDepository Institutions289Electronics & Electrical Equipment: 185 dealsElectronics & Electrica…185Holding & Other Investment Offices: 174 dealsHolding & Other Investm…174Instruments, Medical Devices & Optical Goods: 147 dealsInstruments, Medical De…147Oil & Gas Extraction: 124 dealsOil & Gas Extraction124Electric, Gas & Sanitary Services: 119 dealsElectric, Gas & Sanitar…119Communications: 109 dealsCommunications109Insurance Carriers: 106 dealsInsurance Carriers106
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Medtronic Inc
2014-11-21 (filed) · Public merger · $35.19 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$34bnn.a.1.9x
n.a.
DEFM14A
Includes stock
CAREFUSION Corp
2014-10-05 · Public merger · $49.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Griffin Sub
Strategic
Healthcare$10bn12.2x2.8x
26%
DEFM14A
Includes stock
Symmetry Medical Inc.
2014-08-04 · Public merger · $7.50 a share
TecoStar Holdings, Inc.
Strategic
Healthcare$434mn.a.1.1x
n.a.
DEFM14A
All cash
Medical Action Industries Inc
2014-06-24 · Public merger · $13.80 a share
Owens & Minor, Inc.
Strategic
Healthcare$306m36.9x1.1x
n.a.
DEFM14A
All cash
Measurement Specialties Inc
2014-06-18 · Public merger · $86.00 a share
TE Connectivity Ltd.
Strategic
Industrials$1.3bn19.0xn.a.
n.a.
DEFM14A
All cash
LVB Acquisition, Inc.
2014-04-24 · Public merger · $8.41 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Zimmer Holdings, Inc.
Strategic
Healthcare$10bn17.7x3.3x
n.a.
DEFM14A
Includes stock
Zygo Corp
2014-04-10 · Public merger · $19.25 a share
AMETEK, Inc.
Strategic
Industrials$267m11.3x1.6x
31%
DEFM14A
All cash
Arthrocare Corp
2014-02-02 · Public merger · $48.25 a share
Smith & Nephew, Inc.
Strategic
Healthcare$1.2bn25.0x3.1x
6%
DEFM14A
All cash
Patient Safety Technologies, Inc
2013-12-31 · Public merger · $2.22 a share
Held out of the multiples: EV / LTM EBITDA 116.1x outside 1x to 75x
Stryker Corporation
Strategic
Healthcare$81m116.1x4.1x
n.a.
DEFM14A
All cash
MAKO Surgical Corp.
2013-09-25 · Public merger · $30.00 a share
Stryker Corporation
Strategic
Healthcare$1.4bnn.a.12.0x
84%
DEFM14A
All cash
Rochester Medical Corporation
2013-09-03 · Public merger · $20.00 a share
Not named in the filing
Unclassified
Healthcare$228m27.5xn.a.
n.a.
DEFM14A
All cash
Meade Instruments Corp
2013-07-16 · Public merger · $4.50 a share
Sunny Optics, Inc.
Strategic
Industrials$6mn.a.n.a.
23%
DEFM14A
All cash
Aradigm Corp
2013-06-24 (filed) · Public merger · $0.12 a share
Not named in the filing
Unclassified
Healthcare$27mn.a.26.6x
n.a.
DEFM14A
All cash
Palomar Medical Technologies LLC
2013-03-17 · Public merger · $6.83 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Plan of Merger
Unclassified
Healthcare$48mn.a.0.6x
14%
DEFM14A
Includes stock
Baxano Surgical, Inc.
2013-03-03 · Public merger · $2.28 a share
TranS1 Inc.
Strategic
Healthcare$41mn.a.2.8x
n.a.
DEFM14A
All cash
Biomimetic Therapeutics, Inc.
2012-11-19 · Public merger · $1.50 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Wright Medical Group, Inc.
Strategic
Healthcare-$2mn.a.-0.9x
n.a.
DEFM14A
Includes stock
Winner Medical Group Inc
2012-07-24 · Public merger · $4.50 a share
Not named in the filing
Unclassified
Healthcare$91mn.a.0.5x
32%
DEFM14A
All cash
Winner Medical Group Inc
2012-07-24 · Take-private · $4.50 a share
Not named in the filing
Unclassified
Healthcare$91mn.a.0.5x
32%
SC 13E3
All cash
Teledyne LeCroy, Inc.
2012-05-28 · Public merger · $14.30 a share
Teledyne Technologies Incorporated
Strategic
Industrials$235mn.a.n.a.
56%
DEFM14A
All cash
Gen Probe Inc
2012-04-29 · Public merger · $82.75 a share
Hologic, Inc.
Strategic
Healthcare$3.7bn21.7x6.3x
20%
DEFM14A
All cash
Enovis CORP
2011-12-19 (filed) · Public merger · $23.04 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Not named in the filing
Unclassified
Healthcare$1.0bnn.a.1.5x
n.a.
DEFM14A
Includes stock
Sonosite Inc
2011-12-15 · Public merger · $54.00 a share
FUJIFILM Holdings Corporation
Strategic
Healthcare$778mn.a.2.5x
n.a.
DEFM14C
All cash
Synovis Life Technologies Inc
2011-12-12 · Public merger · $28.00 a share
Baxter International Inc.
Strategic
Healthcare$254m18.8xn.a.
n.a.
DEFM14A
All cash
Valpey Fisher Corp
2011-11-17 · Public merger · $4.15 a share
CTS Corporation
Strategic
Industrials$15mn.a.n.a.
63%
DEFM14A
All cash
Caliper Life Sciences Inc
2011-09-07 · Public merger · $10.50 a share
PerkinElmer, Inc.
Strategic
Industrials$532mn.a.n.a.
n.a.
42% to VWAP
DEFM14A
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More